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INTRODUCTION
Rupture of abdominal aortic aneurysm
(AAA) is a leading cause of death in
western societies. Because AAA is gener-
ally asymptomatic, the evaluation of rup-
ture risk and its prediction are challeng-
ing. Until now, the most commonly used
factor to predict AAA rupture is its size
(1–3), and a general rule is to perform
surgery when the diameter is >55 mm.
Nevertheless, growth of AAA is not lin-
ear and highly unpredictable (2,4). In the
current practice, a conservative approach
is often considered for patients with
small AAA. However, they may also
rupture, whereas many undiscovered
aneurysms may grow to a considerable
size without rupture. Therefore, diameter
is not a fully reliable or specific predictor
of the risk of rupture, necessitating the
search for new markers.
Uptake of 18-fluorodeoxyglucose
(FDG) visualized by positron emission
tomography (PET) is currently used to
detect hypermetabolic activity of cells
seen in tumors and inflammatory
processes. Several studies have also
shown that FDG-PET can reliably detect
leukocyte activities in atherosclerosis
(5,6). We previously reported that a focal
uptake of FDG is usually observed in the
aortic wall of patients with rapidly ex-
panding and symptomatic aneurysms
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Rupture of abdominal aortic aneurysm (AAA) is a cause of significant mortality and morbidity in aging populations. Uptake of
18-fluorodeoxyglucose (FDG) detected by positron emission tomography (PET) is observed in the wall of 12% of AAA (A+), with
most of them being symptomatic. We previously showed that the metabolically active areas displayed adventitial inflammation,
medial degeneration and molecular alterations prefacing wall rupture. The aim of this study was to identify new factors predic-
tive of rupture. Transcriptomic analyses were performed in the media and adventitia layers from three types of samples: AAA with-
out FDG uptake (A0) and with FDG uptake (A+), both at the positive spot (A+Pos) and at a paired distant negative site (A+Neg) of
the same aneurysm. Follow-up studies included reverse-transcriptase–polymerase chain reaction (RT-PCR), immunohistochemical
staining and enzyme-linked immunosorbent assay (ELISA). A large number of genes, including matrix metalloproteinases, colla-
gens and cytokines as well as genes involved in osteochondral development, were differentially expressed in the A+Pos compared
with A+Neg. Moreover, a series of genes (notably CCL18) was differentially expressed both in the A+Neg and A+Pos compared with
the A0. A significant increase of CCL18 was also found at the protein level in the aortic wall and in peripheral blood of A+ patients
compared with A0. In conclusion, new factors, including CCL18, involved in the progression of AAA and, potentially, in their rup-
ture were identified by a genome-wide analysis of PET-positive and -negative human aortic tissue samples. Further work is needed
to study their role in AAA destabilization and weakening.
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that are prone to rupture. Our data also
suggest that the FDG-PET–positive spots
may correspond to the future site of rup-
ture (7). They are further characterized
by the presence of a dense inflammatory
infiltrate mainly localized in the adventi-
tia, sometimes organized in tertiary lym-
phoid organs, and by a marked loss of
smooth muscle cells in the media and by
an increased expression of molecules in-
volved in the wall remodeling, notably
matrix metalloproteinases (MMPs) (7).
This study aims to identify genes in-
volved in this metabolic activation po-
tentially related to rupture. A genome-
wide transcriptomic analysis was
performed on biopsies collected from pa-
tients with an FDG uptake both in the
positive spot (A+Pos) and in a distant
negative site of the same aneurysm
(A+Neg). These paired biopsies were fur-
ther compared with samples collected
from AAA patients with no FDG uptake
(A0) to discriminate biological alterations
associated with FDG uptake, to detect
new systemic biomarkers correlated with
a higher risk of rupture and to identify
new pathways involved in the progres-
sion and rupture of AAA.
MATERIALS AND METHODS
Patients and PET Computed
Tomography Image Acquisition
The investigation conformed to the
principals outlined in the Declaration of
Helsinki. All patients gave written in-
formed consent for the use of the aortic
tissue and serum samples for research.
The collection of the human samples was
approved by the Ethics Committee of the
University Hospital of Liège.
PET computed tomography (PET-CT)
data were acquired in two hospitals (CHU
and CHC), using either a Gemini BB (16-
slice CT; Philips, Bruxelles, Belgium) or a
Discovery LS (16-slice CT; GE Healthcare,
Little Chalfont, UK). The image acquisi-
tion protocol was performed as previ-
ously described (7). The standardized up-
take value (SUV) of the positive spot was
expressed as the ratio between the uptake
in the AAA and the liver (rSUV), with
each patient acting as his or her own con-
trol. Patients with known connective tis-
sue disorders or thoraco-AAAs were ex-
cluded from the study.
Tissue and Blood Collection
The number of samples available for
the various analytical procedures was
variable depending on clinical or practi-
cal reasons (no operation, biopsy not
available, sample of poor quality or of too
small size to allow all types of analyses).
In A0 patients, a biopsy was collected at
the time of surgery in the anterior
aneurysmal wall. For A+ patients, two
fragments were collected: one at the site
of FDG uptake (A+Pos), as localized using
anatomical landmarks and CT images as
detailed previously (7), and a second taken
at a distant site negative for FDG uptake
(A+Neg). A full thickness slice of the sam-
ples was fixed in 4% paraformaldehyde
for histological and immunohistochemical
analysis. When available, the remaining
tissue was dissected to separate the media
and adventitia, snap-frozen in liquid ni-
trogen and kept at –80°C until use.
Blood samples were collected from all
patients undergoing a PET-CT exam (n =
33) and from 12 healthy individuals.
Serum was separated by centrifugation
for 10 min at 3,000g.
Microarray Analyses
Among the 12 AAA patients enrolled
in the transcriptomic study (Table 1 and
Supplementary Table S1), 6 patients had
no visible FDG uptake (A0), whereas 6
others presented positive spots (A+Pos)
localized within a larger negative area
(A+Neg). Demographic information, AAA
size and rSUV on these patients are pre-
sented in Supplementary Table S1. Tissue
samples were ground at liquid nitrogen
temperature (Dismembrator apparatus; 
B. Braun, Berlin, Germany). Total RNA
was extracted with TriPure extraction
reagen (Roche Diagnostics Corporation,
Indianapolis, IN USA) or the RiboPure™
kit (Ambion [Thermo Fisher Scientific
Inc., Waltham, MA, USA]) according to
the manufacturer’s instructions. Total
RNA was quantified (NanoDrop; Isogen
Life Science, De Meern, the Netherlands),
and its quality (expressed by the RNA
quality indicator) was assessed by the
Experion Automated Electrophoresis
System (Bio-Rad). Three to five RNA
samples from each group (adventitia and
media of A0, A+Pos or A+Neg samples)
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Table 1. Clinical features of patients without (A0) and with FDG uptake (A+) used for
transcriptomic study.
RNA pool RNA pool 
Patient ID AAA size (mm) rSUV (media layer) (adventitia layer)
A0
1 60 0.33 X X
2 55 0.41 X
3 57 0.18 X
4 80 0.76 X
5 56 0.43 X
6 53 0.58 X X
Median (IQR) 56.5 (55.3–59.3) 0.40 (0.35–0.54)
A+
7 52 1.04 X X
8 54 0.89 X
9 40 1.93 X X
10 55 1.22 X X
11 67 0.89 X
12 57 0.97 X X
Median (IQR) 54.5 (52.5–56.5) 1.00a (0.91–1.18)
Standardized uptake value ratio (rSUV): aortic SUVmax/hepatic SUVmax. 
ap < 0.001 using Mann-Whitney U test.
with RNA quality indicator values ≥7
were pooled in equal concentration
(Table 1). A total of 500 ng pooled RNA
was labeled by using the GeneChip Ex-
pression 3′-Amplification One-Cycle Tar-
get Labeling Kit (Affymetrix, Santa
Clara, CA, USA) following the manufac-
turer’s protocol. The cRNA was hy-
bridized to the whole human genome
U133Plus2.0 chip (Affymetrix) according
to the manufacturer’s protocol. The data
were generated with the MAS 5.0 algo-
rithm included in the GeneChip Operat-
ing Software. Validations of microarray
data were performed by real-time quan-
titative reverse-transcriptase–polymerase
chain reaction (qRT-PCR) on individual
RNA samples using gene-specific primer
pairs (Supplementary Table S2).
The negative (A+Neg) and positive
(A+Pos) sites of A+ patients were com-
pared with each other and with samples
of the A0 patients. Each comparison was
performed separately for the media and
the adventitia. A fold-change of ≥2 was
used to select differentially expressed
genes across the six comparisons. Lists
of differentially expressed genes were
imported into the DAVID software for
analysis (8,9) and examined for biologi-
cally relevant associations by using the
Gene Ontology (GO) and Kyoto Ency-
clopedia of Genes and Genome (KEGG)
pathway analysis (10). Enriched KEGG
pathways were considered to be signifi-
cant when the modified Fisher exact
p value (Ease Score) was <0.05. National
Center for Biotechnology Information




Microarray data were validated for
selected genes of interest by real-time
qRT-PCR on RNA from individual sam-
ples. Briefly, 500 ng total RNA was 
reverse-transcribed using SuperScript II
Reverse Transcriptase (Invitrogen
[Thermo Fisher Scientific]). Real-time
PCR was performed in a final volume of
20 μL containing cDNA corresponding
to 1 ng mRNA, 2 μmol/L of each primer
and 10 μL of the qPCR MasterMix Plus
for SYBR-Green (Eurogentec, Liège, Bel-
gium) in the ABI Prism 7300 Sequence
Detection System (Applied Biosystems
[Thermo Fisher Scientific]). A dilution
curve of a reference cDNA was per-
formed for each gene product to calcu-
late the reaction efficiency. Data were
further standardized by using the geo-
metrical mean of GAPDH and β2 mi-
croglobulin expression. These two genes
were similarly expressed in all samples
(data not shown). Primer sequences are
listed in Supplementary Table S2.
Immunological Assays
For immunohistochemical analyses,
5-μm sections from 22 paraffin-embed-
ded AAA specimens (10 A0, 5 A+Neg and
7 A+Pos) were stained by using antibodies
against CCL18 (Abcam ab104867; 1/500;
Abcam, Cambridge, UK) and collagen
type X (Abcam ab49945; 1/1,000). Briefly,
antigen retrieval was achieved with 2.5%
trypsin solution (Gibco, Invitrogen
[Thermo Fisher Scientific]) (10 min at
37°C), and the samples were incubated
with the primary antibody overnight at
4°C (in 10% bovine serum albumin).
 Peroxidase-conjugated secondary anti-
body (Dako, Glostrup, Denmark) was
detected using AEC substrate (Dako).
The CCL18 labeling was quantified by
counting the number of positive cells in
10 fields at high magnification (×400).
The collagen × staining was evaluated by
computer-assisted image analysis (Im-
ageJ software; National Institutes of
Health, Bethesda, MD; [11]). The results
were expressed in arbitrary units per sur-
face unit.
For enzyme-linked immunosorbent
assay (ELISA), proteins were extracted
from separated media and adventitia lay-
ers of the aortic wall samples (n = 10 for
A0 and n = 6 for A+ patients at the A+Pos
and A+Neg sites). Tissues were homoge-
nized in a buffer containing 0.05 mol/L
Tris-HCl (pH 7.2), 0.15 mol/L NaCl,
0.002 mol/L CaCl2 and 2 mol/L urea.
Serum samples were collected from 12
healthy donors and 33 AAA patients (17
A0 and 16 A+). CCL18 protein levels
were measured in tissue extracts and
serum by ELISA according to the manu-
facturer’s instructions (R&D Systems,
Minneapolis, MN, USA).
Statistical Analysis
Results were expressed as the median
and the interquartile range (IQR) and
considered to be significant at the 5%
critical level (p < 0.05) by using the
Mann-Whitney U test for unpaired sam-
ples or the Wilcoxon signed-rank test for
paired samples, as implemented in the
Graphpad Prism software (GraphPad
Software; GraphPad, La Jolla, CA, USA).
Correlation between qRT-PCR and mi-
croarray data was calculated by using
the Spearman test for nonparametric val-
ues as implemented in the GraphPad
Prism software.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Transcriptomic Analyses to Compare
Expression in FDG-Positive
and -Negative Aortic Tissue Samples
Taken from the Media and Adventitia
Layers
For the transcriptomic study, we used
pooled RNA samples from patients with
similar clinical features (Table 1 and Sup-
plementary Table S1). In this population,
six patients did not show any significant
FDG uptake in the aneurysmal wall (A0
samples), whereas six others presented
focal uptake spots (A+Pos samples)
within a much larger region with no up-
take (A+Neg samples). The median aortic
diameter was similar in both groups
(Table 1). These three types of samples
were compared with each other
(A+Pos/A0; A+Pos/A+Neg; A+Neg/A0) in
the media and adventitia layers. In this
experimental setting, genes that are mod-
ulated in a similar way both in the A+Pos
and A+Neg compared with A0 likely re-
flect general alterations of the wall biol-
ogy in patients with FDG uptake,
whereas comparisons between the A+Pos
and the A+Neg in the same aneurysm give
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insights into more local activation
processes at sites potentially more prone
to rupture. Using a twofold difference in
expression as a cutoff, the six different
comparisons identified several hundreds
of genes (Figure 1 and Supplementary
Table S3; detailed lists are provided in
Supplementary Tables S4–S9).
On the basis of pathophysiological
knowledge and hypotheses, 13 differen-
tially expressed genes were selected for
follow-up studies. Primer pairs (Supple-
mentary Table S2) were designed for val-
idation of microarray data by qRT-PCR
by using individual RNA samples of the
media and adventitia layers. Among the
58 comparisons reported in Table S10
and S11, the microarray and qRT-PCR re-
sults were in agreement in that most of
the ratios determined from microarray
data were within the range of the values
obtained by qRT-PCR. A significant
Spearman correlation was found be-
tween the microarray and the qRT-PCR
results (Figure 2). Altogether, these data
demonstrate the reliability of the ge-
nome-wide transcriptomic analyses.
Pathway Analysis of Differentially
Expressed Genes
To determine the functions of the dif-
ferentially expressed genes, we used the
DAVID software to classify the genes
into biological pathways. The analysis re-
vealed that only approximately 25% of
the differentially expressed genes could
be assigned to KEGG pathways (5–15 de-
pending on the comparisons). Many of
the enriched KEGG pathways participate
to related biological processes, explain-
ing why a significant number of the dif-
ferentially expressed genes can be found
in several pathways.
Comparison between the A+Pos and the
A+Neg showed a significant enrichment
of seven pathways in the media and five
in the adventitia samples (Tables 2 and
3). The identification of pathways related
to the cardiovascular system was ex-
pected and further validated our data.
The two pathways enriched both in the
media and the adventitia (extracellular
matrix [ECM] receptor interaction and
focal adhesion) are related pathways and
probably reflect remodeling of the ECM
occurring in the FDG-positive samples.
Also of interest was the identification of
the cytokine–cytokine receptor interac-
tion pathway potentially indicative of an
immune reaction.
Although the A+Neg and the A0 sam-
ples are both metabolically inactive, their
comparison identified 15 enriched KEGG
pathways in the media (Supplementary
Table S12) and eight in the adventitia
(Supplementary Table S13). Again, many
pathways are directly related to ECM re-
modeling, signaling by soluble factors
and immune reaction.
Identification of Groups of Genes
Relevant to Systemic or Local
Alterations of AAA
Among the differentially expressed
genes (Table S4 to S9), those involved in
extracellular homeostasis (diverse macro-
molecules, collagens, proteases) and in
inflammatory processes (cytokines) were
evaluated more extensively because of
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Figure 2. Correlation between the microarray expression data and real-time qRT-PCR
data. A linear regression was established between the change in gene expression in the
microarray result and the qRT-PCR for 57 comparisons. r = 0.75 and p < 0.0001 using the
Spearman test. A.U., arbitrary unit.
Figure 1. Distribution of differentially ex-
pressed genes in the media (A) and ad-
ventitia (B) layers of AAA patients. Venn
diagram to show the number of genes
with differential expression with a fold-
change ≥2 when comparing the A+Neg to
the A0 patients (–/0), the A+Pos to the A0
(+/0) and the A+Pos to the A+Neg of the
same patient (+/–), in the media (A) and
the adventitia (B).
their potential role in the growth and
rupture of AAA. Insulinlike growth fac-
tors and related molecules were also of
interest, since many members of this
family were differentially expressed. Se-
lected groups of genes showing systemic
or local changes in expression are illus-
trated for the media (Figure 3) and the
adventitia (Figure 4) by using a color
coding. Grey boxes represent genes with
no change in expression (fold-change
<2), whereas red and green represent in-
creasing levels of upregulation or down-
regulation, respectively.
Comparisons of the A+Neg with A0 (–/0
column in Figures 3 and 4) showed many
similarities for transcripts related to ECM
turnover and homeostasis (metallopro-
teases, collagens, osteochondral develop-
ment) in both the media and adventitia.
In contrast, expression of these genes was
strongly altered in A+Pos compared with
the two other conditions (+/– and +/0
columns). For example, two collagenases
(MMP1 and MMP13) were strongly up-
regulated in the media and the adventitia
of the A+Pos samples, although with a
high interindividual variability (Figures 3
and 4). The expression of elastin and
fibulin 5, two major components of the
elastic fibers, was reduced, whereas the
expression of metalloelastase (MMP12)
was strongly upregulated in the adventi-
tia. Some genes related to basement
membrane (LAMA1, LAMA2, LAMB3,
NID1) were also differentially regulated
in the A+Pos sites. The most striking dif-
ferences were found in the group of colla-
gens, mainly fibril-forming collagens I,
III, V and XII. Genes associated with os-
teochondral development were also aber-
rantly regulated in the adventitia, includ-
ing cartilage-specific collagens X and XI,
periostin (POST; a matricellular protein
regulating collagen fibril formation and
biomechanical properties of connective
tissues), transcription factors (RUNX2,
FOXC1) and factors participating in the
Wnt signaling (WNT2, WNT5A, FRZB). A
different situation was observed for cy-
tokine-related genes, with more similari-
ties between A+Pos and A+Neg (more gray
boxes in the +/– columns and more col-
ored boxes in the +/0 and –/0 columns).
Of special interest was the high overex-
pression of IL6 and CCL18 in both the
media and adventitia in the entire wall of
A+ compared with A0 patients, since
these factors are involved in inflamma-
tory processes and could be used as cir-
culating markers.
Increased Protein Production of
CCL18 and Collagen Type X in the
FDG-Positive Aortic Wall Compared
with the FDG-Negative Samples
Protein expression and tissue localiza-
tion of type X collagen were determined
by immunostaining on tissue samples, to
verify the activation of the osteochondral
development pathway in the A+Pos ad-
ventitia samples (Figure 5A). Type X col-
lagen was localized mainly in the adven-
titia, and there was significantly more
staining in the A+Pos tissues compared
with the A0 samples (Figure 5C). How-
ever, differences were less pronounced
than expected from transcriptomic analy-
ses and did not reach statistical signifi-
cance between A+Pos and A+Neg.
Immunostaining also showed CCL18-
positive cells mainly in the adventitia
(Figure 5B) and in the inner part of the
media. A semiquantitative analysis con-
firmed that there was a significantly 
increased number of CCL18-positive
cells in the A+Neg and A+Pos groups (Fig-
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Table 2. Enriched KEGG pathways in the media of the A+Pos versus the A+Neg samples.
Total
genes Modulated
in the genes 
pathway in A+Pos
Pathway (n) (n) p
hsa04512: ECM receptor interaction 84 13 1.8E-04
hsa05412: Arrhythmogenic right ventricular cardiomyopathy 76 12 3.0E-04
hsa04060: Cytokine-cytokine receptor interaction 262 21 7.0E-03
hsa05410: Hypertrophic cardiomyopathy 85 10 9.2E-03
hsa04510: Focal adhesion 201 17 1.0E-02
hsa04514: Cell adhesion molecules 132 12 2.3E-02
hsa05414: Dilated cardiomyopathy 92 9 4.0E-02
Significantly enriched KEGG pathways among the differentially expressed genes in the
media of A+Pos compared with A+Neg were identified by using the DAVID software (8). The
total number of genes in the pathway, the number of modulated genes observed in our
microarray data and the modified Fisher exact p value (Ease Score) are listed.
Table 3. Enriched KEGG pathways in the adventitia of the A+Pos versus the A+Neg.
Total
genes Modulated
in the genes 
pathway in A+Pos
Pathway (n) (n) p
hsa04512: ECM receptor interaction 84 16 1.9E-06
hsa04510: Focal adhesion 201 21 3.1E-04
hsa00380: Tryptophan metabolism 40 8 1.3E-03
hsa04270: Vascular smooth muscle contraction 112 12 7.8E-03
hsa00350: Tyrosine metabolism 44 6 3.8E-02
Significantly enriched KEGG pathways among the differentially expressed genes in the
adventitia of A+Pos compared with A+Neg were identified by using the DAVID software (8).
The total number of genes in the pathway, the number of modulated genes observed in
our microarray data and the modified Fisher exact p value (Ease Score) are indicated.
ure 5D). These data were validated by
ELISA in tissue extracts (Figures 6A, B).
The level of CCL18 was not altered in
the media of the different groups,
whereas it was significantly increased in
the A+Neg adventitia compared with the
A0 patients and was even higher in A+Pos
than in A+Neg. The circulating level of
CCL18 (Figure 6C) was also measured by
ELISA in the serum of 12 healthy donors
(clinical characteristics in Supplementary
Table S14) and 33 AAA patients (17 A0
and 16 A+). CCL18 concentrations were
significantly higher in the AAA patients
compared with the healthy population. A
small but significant difference was also
observed between A0 and A+. The circu-
lating level of CCL18 was not correlated
with the diameter of AAA (r = 0.9, data
not shown).
DISCUSSION
Pathobiology of AAA is complex and
not yet completely understood, although
many pathogenic mechanisms have been
suggested to participate in AAA progres-
sion and rupture (12). Because the major-
ity of AAA patients are asymptomatic,
aneurysms are often detected inciden-
tally. However, aneurysms that produce
symptoms, such as rapid enlargement
and/or severe back or flank pain, are at
increased risk of rupture, an often fatal
complication. Finding new biological
pathways and markers associated with
risk for aneurysm rupture by using ge-
nome-wide approaches has been the
focus of intense research for several
years (10,13–15). These findings will
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Figure 3. Expression of selected gene families in the aortic media on the basis of microarray analysis. Color codes correspond to the fold-
change between the three comparisons: A+Neg compared with A0 (–/0), A+Pos compared with A0 (+/0) and A+Pos compared with A+Neg
(+/–). Arrows designate genes validated by real-time PCR.
allow better understanding of rupture
risk and predicting this ultimate event.
FDG, a metabolic marker used in PET
imaging, accumulates preferentially in
cells with high metabolic activity, such as
tumor cells, activated macrophages and
lymphocytes (16,17). Our cohort of pa-
tients can be divided into patients with
or without significant FDG uptake in the
aneurysmal wall. It is worth noting that
most of the A0 patients were asympto-
matic, whereas a significant number of
A+ patients presented warning signs of
impending rupture. The positive FDG
uptake sites have been shown by us and
others to correspond to the maximal
peak wall stress (18) and to the site of
rupture (19). The novelty of this study
was to analyze media and adventitia lay-
ers separately from three types of surgi-
cal specimen collected either from
aneurysms without any significant FDG
uptake or from positive aneurysms, at
both positive and negative uptake sites.
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Figure 4. Expression of selected gene families in the aortic adventitia on the basis of microarray analysis. Color codes correspond to the
fold-change between the three comparisons: A+Neg compared with A0 (–/0), A+Pos compared with A0 (+/0) and A+Pos compared with
A+Neg (+/–). Arrows designate genes validated by real-time PCR. 
Enriched KEGG pathways were identi-
fied in the different types of samples. In
the media, the cytokine–cytokine recep-
tor interaction pathway was significantly
enriched, suggesting the involvement of
inflammatory mediators in AAA progres-
sion. It is worth noting that some cy-
tokines, such as IL6 and CCL18, were up-
regulated not only in the A+Pos but also
in the A+Neg compared with the A0. This
observation suggests that environmental
events and/or systemic factor(s) might
affect the whole aneurysmal wall and ac-
tivate pathways leading to wall degrada-
tion and weakening. In agreement with
this hypothesis, the majority of A+ pa-
tients presented a significantly increased
preoperative circulating C-reactive pro-
tein (CRP) levels in comparison to A0 pa-
tients (7). CCL18 was highly overex-
pressed throughout the surgical samples
of A+ patients (A+Pos and A+Neg sites in
the media and the adventitia). Its overex-
pression was validated by real-time qRT-
PCR in all the patients of our series and
confirmed at the protein level by ELISA.
Immunohistochemical analyses of the
aortic wall by an anatomopathologist
showed that the main CCL18-producing
cells are macrophages, with a few en-
dothelial cells and fibroblasts. CCL18 is
chemotactic for T and B cells (20), is de-
tected in atherosclerosis plaques in re-
gions rich in macrophages (21) and was
also reported as a fibro-inflammatory
mediator able to stimulate collagen pro-
duction by lung and dermal fibroblasts
(22). In this study, the plasma levels of
CCL18 were significantly higher in the
AAA population compared with healthy
individuals, with the highest concentra-
tions being measured in A+ patients.
These data suggest that CCL18 could be
used as a factor for evaluating the pres-
ence and the metabolic activity of AAA
in combination with potential markers
such as MMP9, which was previously
shown to be correlated with the growth
of AAA in some studies (23) or with 
C-reactive protein, which is increased in
A+ patients (7).
The inflammatory environment, espe-
cially exacerbated in the A+Pos, certainly
contributes to the intense ECM remodel-
ing occurring during AAA progression
(24) and ultimately leading to its rupture.
According to this hypothesis, Dihlmann
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Figure 5. Immunostaining of collagen type X (A and C) and CCL18 (B and D). Full-thickness aortic wall sections from representative pa-
tients with a PET-negative (A0) or a PET-positive (A+) AAA, at the negative (A+Neg) and the positive site (A+Pos) are shown. Semiquantita-
tive analysis in A0 (n = 10), A+Neg (n = 5) and A+Pos (n = 7) for the collagen type X (C) staining and CCL18 (D) was carried out. **p < 0.01
and ***p < 0.001 using Mann-Whitney U test or Wilcoxon signed rank test for paired samples. Scale bar in collagen type X sections = 200
μm and in CCL18 sections = 50 μm.
et al. (25) demonstrated recently that the
inflammasome process was activated in
the AAA wall at the site identified as high
rupture risk areas by finite element analy-
sis (25). ECM receptor interaction and
focal adhesion KEGG pathways were
modified both in the media and in the ad-
ventitia of AAA, mostly due to the differ-
ential expression of collagens and adhe-
sion molecules such as integrins. On the
basis of these data and on previous publi-
cations demonstrating the involvement of
MMP2 and MMP9 in the growth and rup-
ture of AAA (26–29), the expression of
genes involved in ECM accumulation and
remodeling were studied in more detail.
We found that the expressions of several
MMPs, notably collagenases (MMP1,
MMP8 and MMP13), elastases (MMP9
and MMP12), matrilysin (MMP7) and
MT1-MMP, the main activator of MMP2,
are all upregulated in the A+Pos samples.
Of special interest, we measured in the
adventitia a >10-fold increase of MMP1 in
the A+Pos compared with the A+Neg, and
the expression of MMP13, which was ab-
sent in the A0 and weakly expressed in
the A+Neg, was also strongly upregulated
in the A+Pos. MMP13 has been shown to
play a crucial role in chronic inflamma-
tory diseases (30) and is increased in AAA
(31). The presence of these collagenases at
the FDG uptake site could contribute to
the degradation of fibrillar collagens I and
III, which provide the ultimate tensile
strength to the aorta. This scenario could
result in a progressive weakening of the
wall and finally its rupture (32).
A tentative repair process by the ad-
ventitial cells has been previously sug-
gested by the increased expression of
COL1A1, a main fibrillar structural com-
ponent of the adventitia (33,34). We have
extended this observation in our microar-
ray analysis. Besides increased expression
of type I, III and V fibril-forming colla-
gens, many others collagen types were
also overexpressed in the A+Pos, notably
COL10A1 and COL11A1, two collagen
types predominantly localized in carti-
lage and vitreous body. COL10A1 is ex-
pressed by hypertrophic chondrocytes
during endochondral ossification (35),
whereas COL11A1, besides its cartilagi-
nous expression, has been found in peri-
tumoral myofibroblasts (36). Interestingly,
a number of other genes involved in car-
tilage and bone development were also
upregulated in the A+Pos in the adventi-
tia. Among them, periostin (POSTN), a
matricellular protein involved in cell ad-
hesion, was first identified in osteoblastic
cells (37) and was recently described to
be involved in AAA development (38).
POSTN localizes mainly in bone but has
been also found in fibrous connective tis-
sues subjected to mechanical stress such
as heart valves and tendons and in sev-
eral types of tumors (rev. in 37). It is also
overexpressed during vascular injury by
proliferative smooth muscle cells to facili-
tate their migration in the adventitia (39).
In a recent proteomic study, POSTN was
reported to be increased in AAA (40). Al-
together, these original data suggest that
cells in the adventitial tissue with a posi-
tive FDG uptake possess a specific phe-
notype leading to the production of an
inappropriate ECM. The presence and in-
creased levels of collagen type X protein
observed by immunostaining in AAA
walls further support this hypothesis.
The nature of these cells and their rela-
tionship to progenitor lineage need fur-
ther investigation.
CONCLUSION
The global gene expression analysis
performed here on FDG-positive
and -negative aortic tissue samples iden-
tified several genes, such as CCL18, po-
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Figure 6. CCL18 protein levels in the aortic wall (A and B) and serum (C) of AAA patients
measured by ELISA. Box and whiskers plots of protein levels of CCL18 are shown. CCL18
was measured in the media (A) and adventitia (B) of A0 (n = 11), A+Neg (n = 6) and A+Pos
(n = 7) aortic wall samples. Circulating CCL18 (C) was measured in the serum of healthy
people (n = 12) and AAA patients (n = 33; 17 A0 and 16 A+). *p < 0.05 and ***p < 0.001
using Mann-Whitney U test or Wilcoxon signed rank test for paired samples.
tentially involved in aneurysm progres-
sion and rupture. Further studies on
larger populations of patients are needed
to replicate the findings and assess their
clinical value.
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